Search
Menu
Home
HTB
2000
May
15
HTB
15 May 2000
Contents
Treatment alerts
EMEA public statement on Viramune (nevirapine): severe and life-threatening cutaneous and hepatic reactions
Conference reports
Third International Workshop on Salvage Therapy for HIV Infection, April 12-14, 2000, Chicago, USA
Clinical studies of indinavir/ritonavir as salvage therapy
Indinavir plus ritonavir: might exposure to higher levels of indinavir overcome protease resistant HIV and prove useful to ‘rescue’ previously failed protease inhibitor based combinations?
First International Workshop in Clinical Pharmacology in HIV Therapy, 30-31 March 2000, Noordwijk, Netherlands
TDM: standardisation and quality control
TDM in clinical practice
ATHENA – Early results from first randomised study of clinical benefits of TDM
TDM for individualising dosing – practicality and efficacy for PIs and RTIs
TDM and adherence
Drug interactions: amprenavir, saquinavir, ABT-378/r (lopinavir/r), indinavir, efavirenz, ritonavir
L-Acetyl Carnitine (LAC) improves symptoms of peripheral neuropathy (PN): evidence for increases in cutaneous innervation
Antiretrovirals
ABT-378/r (lopinavir) now available on named patient basis in UK
Enteric coated ddI available on named patient basis in UK
Nelfinavir potency concerns
Treatment strategies
GM-CSF beneficial for patients with advanced HIV disease
Paediatric care
Liquid formulation of efavirenz available for children in the uk on named patient basis
Most reconstituted CD4 cells naive after HAART in children with HIV
Side effects
Decreased bone mineral density and HIV protease inhibitors
Virology
A view from the lab: interview with Professor Clive Loveday
HTB RSS
Current issues
March 2024
February 2024
January 2024
Back issues
Special report
Modelling study challenges links between gender and PrEP: event-based dosing and easier daily dosing should work for all
12 February 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage